Monte Rosa: 5.5% Stake Reported by TCG/Chen Yu
Monte Rosa Therapeutics, Inc. Schedule 13G/A amendment reports that the Reporting Persons collectively hold 4,622,151 shares of Common Stock, representing 5.5% of the class based on 84,479,418 shares outstanding as of May 1, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Monte Rosa Therapeutics, Inc. Schedule 13G/A amendment reports that the Reporting Persons collectively hold 4,622,151 shares of Common Stock, representing 5.5% of the class based on 84,479,418 shares outstanding as of May 1, 2026. The holdings consist of two fund vehicles each holding 2,311,076 and 2,311,075 shares, and the reporting individual, Chen Yu, is disclosed as sharing voting and dispositive power through related general partner entities.
The filing clarifies ownership and voting/dispositive arrangements under Rule 13d-1(k)(1) and includes the reporting persons' address and organizational details. The statement notes potential shared voting and investment power among the named entities and that the Reporting Persons disclaim group status.
Insights
Large holder reports a >5% stake via fund entities and shared control.
The filing documents that TCG Crossover II and TCG Crossover III each hold approximately 2,311,076 and 2,311,075 shares respectively, and that Chen Yu shares voting and dispositive power through the GP entities. The filing cites May 1, 2026 outstanding shares of 84,479,418 as the basis for the 5.5% figure.
Cash-flow treatment and transaction history are not provided in the excerpt; subsequent filings would show any changes. Filings of this type primarily update ownership disclosures and the structure of control affiliations.
Clarifies attribution and voting/dispositive relationships among funds, GPs, and an individual.
The statement attaches comments that the securities are held of record by fund entities and that GPs (TCG Crossover GP II/III) may be deemed to have voting and investment power. It also explains that the Reporting Persons expressly disclaim group status while filing jointly under Rule 13d-1(k)(1).
Key items to watch in future filings include any change in percent ownership relative to the May 1, 2026 outstanding share base and any amendments that alter voting or dispositive power.
Key Figures
Key Terms
beneficially owned regulatory
Rule 13d-1(k)(1) regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How was the 5.5% ownership calculated in the GLUE Schedule 13G/A?
Does the Schedule 13G/A assert a group status for these reporting persons for GLUE?
What address and organizational details are provided in the GLUE amendment?
AI-generated analysis. How Rhea-AI works. Not financial advice.